MHMia Husić

Mia Husić

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mia Husić has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MetaFusion: A high-confidence metacaller for filtering and prioritizing RNA-seq gene fusion candidates

    by Michael Apostolides, Yue Jiang, Mia Husić, Robert Siddaway, Cynthia Hawkins, Andrei L. Turinsky, Michael Brudno, Arun K. Ramani

    Motivation Gene fusions are often associated with cancer, yet current fusion detection tools vary in their calling approaches, making selecting the right tool challenging. Ensemble fusion calling techniques appear promising; however, current options have limited accessibility and function. Results MetaFusion is a flexible meta-calling tool that amalgamates the outputs from any number of fusion callers. Results from individual callers are converted into Common Fusion Format, a new file type that standardizes outputs from callers. Calls are then annotated, merged using graph clustering, filtered and ranked to provide a final output of high confidence candidates. MetaFusion consistently outperformed individual callers with respect to recall and precision on real and simulated datasets, achieving up to 100% precision. Thus, an ensemble calling approach is imperative for high confidence results. MetaFusion also labels fusions found in databases using the FusionAnnotator package, and is provided with a benchmarking toolkit to calibrate new callers. Availability MetaFusion is freely available at https://github.com/ccmbioinfo/MetaFusion Contact arun.ramani{at}sickkids.ca

  • Open Access

    CReSCENT: CanceR Single Cell ExpressioN Toolkit

    by Suluxan Mohanraj, J. Javier Díaz-Mejía, Martin D. Pham, Hillary Elrick, Mia Husić, Shaikh Rashid, Ping Luo, Prabnur Bal, Kevin Lu, Samarth Patel, et al.

    CReSCENT: CanceR Single Cell ExpressioN Toolkit ( https://crescent.cloud ), is an intuitive and scalable web portal incorporating a containerized pipeline execution engine for standardized analysis of single-cell RNA sequencing (scRNA-seq) data. While scRNA-seq data for tumour specimens are readily generated, subsequent analysis requires high-performance computing infrastructure and user expertise to build analysis pipelines and tailor interpretation for cancer biology. CReSCENT uses public data sets and preconfigured pipelines that are accessible to computational biology non-experts and are user-editable to allow optimization, comparison, and reanalysis for specific experiments. Users can also upload their own scRNA-seq data for analysis and results can be kept private or shared with other users.


  • Open Access

    Found in Transcription: Gene fusions arise through defects in RNA processing in the absence of chromosomal rearrangements

    by Yue Jiang, Michael J. Apostolides, Mia Husić, Robert Siddaway, Man Yu, Stephanie Mark, Arun K. Ramani, Cynthia Hawkins, Michael Brudno

    Recent advancements in high throughput sequencing analysis have enabled the characterization of cancer-driving fusions, improving our understanding of cancer development. Most fusion calling methods, however, examine either RNA or DNA information alone and are limited to a rigid definition of what constitutes a fusion. For this study we developed a pipeline that incorporates several fusion calling methods and considers both RNA and DNA to capture a more complete representation of the tumour fusion landscape. Interestingly, most of the fusions we identified were specific to RNA, with no evidence of corresponding genomic restructuring. Further, while the average total number of fusions in tumour and normal brain tissue samples is comparable, their overall fusion profiles vary significantly. Tumours have an over-representation of fusions occurring between coding genes, whereas fusions involving intergenic or non-coding regions comprised the vast majority of those in normals. Tumours were also more abundant in unique, sample-specific fusions compared to normals, though several fusions exhibited strong recurrence in the tumour type examined (diffuse intrinsic pontine glioma; DIPG) and were absent from both normal tissues and other cancers. Intriguingly, tumours also show broad up- or down-regulation of spliceosomal gene expression, which significantly correlates with fusion number (p=0.007). Our results show that RNA-specific fusions are abundant in both tumour and normal tissue and are associated with spliceosomal gene dysregulation. RNA-specific fusions should be considered as a potential mechanism that may contribute to cancer formation initiation and maintenance alongside more traditional structural events.

  • A novel role of the corticotrophin‐releasing hormone regulating peptide, teneurin C‐terminal associated peptide 1, on glucose uptake into the brain

    by D. W. Hogg, Y. Chen, A. L. D'AQuila, M. Xu, M. Husić, L. A. Tan, C. Bull, D. A. Lovejoy

    Teneurin C‐terminal associated peptide (TCAP) is an ancient paracrine signalling agent that evolved via lateral gene transfer from prokaryotes into an early metazoan ancestor. Although it bears structural similarity to corticotrophin‐releasing hormone (CRH), it inhibits the in vivo actions of CRH. The TCAPs are highly expressed in neurones, where they induce rapid cytoskeletal rearrangement and are neuroprotective. Because these processes are highly energy‐dependent, this suggests that TCAP has the potential to regulate glucose uptake because glucose is the primary energy substrate in brain, and neurones require a steady supply to meet the high metabolic demands of neuronal communication. Therefore, the objective of the present study was to assess the effect of TCAP‐mediated glucose uptake in the brain and in neuronal cell models. TCAP‐mediated 18F‐deoxyglucose (FDG) uptake into brain tissue was assessed in male wild‐type Wistar rats by functional positron emission tomography. TCAP‐1 increased FDG uptake by over 40% into cortical regions of the brain, demonstrating that TCAP‐1 can significantly enhance glucose supply. Importantly, a single nanomolar injection of TCAP‐1 increased brain glucose after 3 days and decreased blood glucose after 1 week. This is corroborated by a decreased serum concentration of insulin and an increased serum concentration of glucagon. In immortalised hypothalamic neurones, TCAP‐1 increased ATP production and enhanced glucose uptake by increasing glucose transporter recruitment to the plasma membrane likely via AKT and mitogen‐activated protein kinase/ERK phosphorylation events. Taken together, these data demonstrate that TCAP‐1 increases glucose metabolism in neurones, and may represent a peptide signalling agent that regulated glucose uptake before insulin and related peptides.


  • Corticotropin-Releasing Hormone Peptide Family

    by David W. Hogg, Mia Husic, David A. Lovejoy